Testing for EGFR mutations, ALK rearrangements is cost-effective in NSCLC.

29 enero 2015

Multiplexed genetic screening for epidermal growth factor receptor and anaplastic lymphoma kinase gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer setting in the United States, researchers report.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/IwGmqs1IH9w/150129170400.htm

Volver